article thumbnail

AI IN PHARMACEUTICAL MARKETING: Optimizing Automation and Expertise

PM360

Applying AI to GVDs Amassing comprehensive productand market-related data, GVDs demonstrate the value of a pharmaceutical product to various stakeholders, including payers, healthcare providers, and regulatory bodies. It leveraged experts input at key points in the process, to assess and validate the work.

article thumbnail

Economics and risks of FDA’s Quality management maturity rating programme

European Pharmaceutical Review

The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) through the Office of Pharmaceutical Quality in 2021 embarked on an initiative to develop a framework for establishing a pharmaceutical manufacturing site quality rating system, the Quality management maturity (QMM) programme.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Top-10 ways for Pharma to leverage AI according to…AI

Impetus Digital

Manufacturing Optimization While the manufacturing industry lags behind others in terms of AI uptake, there is no shortage of potential ways to leverage this technology.

Pharma 92
article thumbnail

Trends in Virtual Collaboration

Impetus Digital

In these online programs, a handful of carefully selected KOLs attending the congress are asked to summarize abstracts that will be of special interest to other healthcare providers from their country/region or specialty. In short, it is all about catering to different preferences at the same time.

article thumbnail

Diversity and inclusion in oncology clinical trials

Clarify Health

With the myriad of guidance and recommendations to boost diversity and inclusion in oncology trials, , biotech and pharmaceutical manufacturers are left to interpret the criteria and implement them through tangible action. Clarify launched its real-world evidence on health disparities in 2021.

article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

Pharmaceutical manufacturers have submitted Citizen Petitions raising safety or efficacy concerns about proposed competing generic and biosimilar products, and such submissions often delay FDA approval of the proposed products while the FDA resolves the pending petitions.

article thumbnail

Getting ahead of regulatory changes around PFAS in pharmaceutical packaging

Clarivate

Nitrosamines have garnered significant attention from the pharmaceutical industry due to their detection in commonly prescribed medications for conditions like type 2 diabetes, high blood pressure, and heartburn. [1] Manufacturers, healthcare providers, and consumers alike face the need to quickly adapt.